Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244532 | 1.00 | HSD17B10 (0.48) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL8223462 | 1.00 | HSD17B10 (0.48) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL20586375 | 0.81 | ALDH1A1 (0.44) | NFE2L2CYP1A2MAOBMAOATDP1 | |
| SCHEMBL20586377 | 0.81 | ALDH1A1 (0.44) | NFE2L2CYP1A2MAOBMAOATDP1 | |
| SCHEMBL15899333 | 0.77 | NFE2L2 (0.61) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL6520362 | 0.77 | NFE2L2 (0.61) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL18416523 | 0.75 | HSD17B10 (0.84) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL699666 | 0.72 | AHR (0.74) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL20582895 | 0.72 | AHR (0.74) | HSD17B10NFE2L2AHRCYP1A2FBP1 | |
| SCHEMBL843718 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2057162-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | Sepracor Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005456-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | DAO, DDO, AOX1 | HSD17B10 1387/4885NFE2L2 1055/4885AHR 2121/4885 |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | DAO, DDO, AOX1 | HSD17B10 2258/4885NFE2L2 1607/4885AHR 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.